

## **Carsten Reinhardt Joins Micromet to Head Its Clinical Development Team**

### **Additional expertise in the development and marketing of antibodies will further strengthen Micromet's drug development**

June 6, 2005, Munich, Germany -- Micromet AG welcomes Carsten Reinhardt, M.D., Ph.D. as its new Senior Vice President, Clinical Development. Dr Reinhardt joins Micromet from Roche, where he was the International Medical Leader for the Herceptin(R) Program. His previous assignments include Head of Clinical Development at Fresenius Biotech and academic positions at University Hospitals in Munich, Tübingen, and Mount Sinai in New York, as well as research positions at the Max Planck Institute and the Institute of Immunology, both in Munich.

"Carsten's experience with a highly successful and well marketed monoclonal antibody in oncology and his strong background in immunology splendidly match with our clinical programs and pipeline of novel immunotherapeutics," said Dr Christian Itin, CEO of Micromet. "With Carsten's insight, we look forward to further shaping the profile of our clinical candidates: MT201 (adecatumumab), a fully human monoclonal antibody, which is in two phase II clinical trials in metastatic breast cancer and prostate cancer; and our BiTE(TM) MT103, which is in a phase I trial in B cell lymphoma. Moreover, Carsten will be key in bringing several new human antibodies and BiTE(TM) candidates into clinical development."

"The recent results of Herceptin(R) in the adjuvant treatment of breast cancer patients show unprecedented activity and emphasize the need for additional antibody-based approaches in targeted cancer therapy. Micromet's MT201, which binds to Ep-CAM, a target antigen being expressed in most human cancers, appears to be highly suited to improve the treatment of major cancer indications," commented Dr. Reinhardt. "In addition, Micromet's BiTE(TM) platform, with its unique mechanism of action, has shown exciting preclinical activity and has the potential to improve the treatment of lymphomas and solid tumors. I am therefore looking forward to heading this excellent clinical team and to being a part of this exciting company."

MT201 is in a partnership with Serono, SA (Geneva, Switzerland) and MT103 is in a partnership with MedImmune, Inc. (Gaithersburg, MD., USA). ###

#### **Contact Information**

*Media:* Evelyn Wolf, Phone: +49 89 895277-220, Email: [evelyn.wolf@micromet.de](mailto:evelyn.wolf@micromet.de)

*Investors:* Ines-Regina Buth, Phone: +49 89 895277-221, Email: [ines-regina.buth@micromet.de](mailto:ines-regina.buth@micromet.de)

Micromet AG, Staffelseestr. 2, 81477 Munich, Germany

#### **About Micromet AG**

Micromet AG, a private Munich-based biotechnology company, puts novel concepts in immunotherapy to work. Using proprietary technologies, the Company is building a strong pipeline of innovative drug candidates for the treatment of cancer, inflammation and autoimmune disease. Two candidates are currently in clinical trials. The Company has established a powerful drug development platform based on its BiTE(tm) technology ("Bispecific T cell engagers"), a unique drug format that leverages the outstanding cytotoxic potential of T cells, the most powerful 'killer cells' of the human immune system. In addition, Micromet is exploiting the potential of SCAs (single-chain antibodies) for the development of novel drugs under a multiyear strategic collaboration with Enzon Inc. Micromet has integrated infrastructure and expertise in all disciplines of drug design and development. The Company has attracted both top-tier life-science investors and corporate partners such as MedImmune, Inc., Enzon Pharmaceuticals, Inc. and Serono. For further information, please visit the Company's web site at [www.micromet.de](http://www.micromet.de).